Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.
- Phase 3 PARA_OA_012 trial surpasses 50% patient dosing milestone
- A$14 million placement upsized from A$8 million due to strong demand
- Share Purchase Plan launched to raise up to A$2 million
- Pro forma cash position of approximately A$45 million post-raise
- Interim analysis targeted for Q3 2026, with top-line readout in Q1 2027
Capital Raise Upsizes to Support Critical Phase 3 Milestones
Paradigm Biopharmaceuticals (ASX:PAR) has successfully upsized its recent capital raise, completing a A$14 million placement, significantly above the initial A$8 million target, reflecting robust investor appetite. Alongside this, the company launched a Share Purchase Plan (SPP) aiming to raise an additional A$2 million from eligible shareholders. The combined capital boost lifts Paradigm’s pro forma funding to around A$45 million, providing a solid financial runway through the upcoming interim analysis of its pivotal Phase 3 knee osteoarthritis trial and into the post-interim period.
The placement shares were issued at A$0.19 each, representing a 15.6% discount to the last traded price, with attaching options exercisable at a 25% premium, subject to shareholder approval. This structure offers investors potential upside aligned with the trial’s key data milestones.
Phase 3 Trial Progress Accelerates with Global Expansion
Paradigm’s Phase 3 PARA_OA_012 trial, evaluating injectable pentosan polysulfate sodium (iPPS) for moderate to severe knee osteoarthritis pain, has now dosed over 50% of its target 466 patients. This milestone clears the path for the planned interim analysis expected in Q3 2026, when approximately half the participants will have reached the Day 112 primary endpoint assessment.
Recruitment momentum continues across a global network spanning Australia, the United States, Asia, and newly activated sites in Hong Kong and Moldova, enhancing geographic diversity and enrolment efficiency. The trial design closely mirrors the successful Phase 2 PARA_OA_008 study, incorporating refinements like the weekly average daily pain score to better manage placebo effects, a notorious challenge in osteoarthritis trials.
Paradigm’s dual-CRO model, leveraging Advanced Clinical and Nordic Bioscience Clinical Development, supports operational flexibility and robust data capture as the study scales. An independent Data Safety Monitoring Board (DSMB) is overseeing safety, with a review underway based on 20% of participants dosed.
Scientific Validation Bolsters Clinical Confidence
Recent peer-reviewed publications underpin Paradigm’s scientific rationale. The Phase 2 PARA_OA_008 biomarker study demonstrated iPPS’s favourable impact on cartilage degradation, inflammation, and pain biomarkers, offering mechanistic validation for the Phase 3 program. Complementing this, a translational canine osteoarthritis study published in PLOS One showed sustained pain relief, functional improvement, and structural benefits over six months, reinforcing the durability and disease-modifying potential of PPS.
Further research collaborations, including one with City St George’s, University of London, are underway to explore PPS’s effects on bone marrow lesions, a key driver of osteoarthritis progression, using advanced MRI and molecular profiling.
Financial Position and Outlook
As at 31 March 2026, Paradigm held A$11.3 million in cash, supplemented by a US$27 million convertible note facility with Obsidian Global Partners. During the quarter, Paradigm drew down an additional US$5 million tranche, with US$10 million remaining undrawn, providing further liquidity. The recent capital raise reduces reliance on this facility by enabling partial repayment, enhancing capital structure flexibility.
Operating cash outflows for the June quarter are forecast between A$14 million and A$16 million, reflecting peak trial activities including recruitment, dosing, and monitoring. The company’s funding is expected to support operations through the interim analysis and into the post-interim period, with top-line Phase 3 results anticipated in Q1 2027.
Paradigm’s Managing Director Paul Rennie highlighted the strong investor demand as a vote of confidence in the Phase 3 program and the upcoming interim readout. He emphasised the company’s focus on maintaining protocol integrity and data quality as it approaches this critical clinical inflection point.
Notably, Chief Medical Officer Dr Donna Skerrett will reduce her working hours but remain engaged in a senior capacity to support clinical and regulatory activities, with a search underway for a full-time replacement to ensure continuity through the trial and regulatory submission phases.
This update follows Paradigm’s recent announcement of reaching the halfway mark in patient dosing Paradigm Reaches Halfway Mark in Phase 3 Osteoarthritis Trial Ahead of August Readout, reinforcing steady progress toward key data milestones.
Bottom Line?
Paradigm’s strengthened balance sheet and accelerating Phase 3 trial set the stage for a pivotal interim analysis that could redefine its clinical and commercial trajectory.
Questions in the middle?
- Will the interim analysis replicate the Phase 2 efficacy signals to validate iPPS’s potential?
- How might Paradigm navigate generic competition risks given PPS’s repurposed status?
- What partnering or licensing opportunities could emerge post-interim analysis to extend the company’s runway?